ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation

C. Choi, A. Han, S. Min, S.-K. Min, T. Lee, I.-M. Jung, S. Kim, J. Ha.

Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.

Meeting: 2015 American Transplant Congress

Abstract number: D208

Keywords: FK506, Immunosuppression, Kidney transplantation, Pediatric

Session Information

Session Name: Poster Session D: Pediatric Clinical Kidney Transplantation

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Purpose

Tacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important to improve medical adherence and to overcome calcineurin inhibitor toxicity, because they are usually required longer time use of immunosuppressants than adult recipients. Advagraf is new tacrolimus agent for once-daily formulation to improve compliance of patients. This study aimed to identify long-term results after conversion from traditional twice-daily tacrolimus to the once-daily tacrolimus in pediatric KT.

Methods

Between July 2011 and January 2012, 34 pediatric KT recipients who received were converted at mean post-transplant period of 1221 ± 675 days (previously reported in Am J Transplant 2013). They were followed up to last days of mean 1130 ± 92 days after conversion. The patients were checked physical examination and laboratory findings including body mass index (BMI), glomerular filtration rate (GFR), Tacrolimus dose and trough level.

Results

Mean age of patients at conversion was 12.3 ± 2.8. Three patients ceased their Advagraf use. Of them, one patient received chemotherapy for Burkitt lymphoma and maintained corticosteroid only, and two patients were re-converted to twice-daily dosing tacrolimus by failing to maintain appropriate trough level of tacrolimus. There was no significant factor that effected on the re-conversion. Adverse effects including one acute T cell mediated rejection and six infectious disease developed in period after 6 months. BMI (1, 2 year after conversion, p=0.014, 0.029), second year GFR (p=0.033) and last trough level of tacrolimus (p=0.038) were risk factors on the adverse effects after conversion. Donor age at transplantation (p=0.008) and recipient age at conversion to advagraf (p=0.029) had negative correlation to GFR at last follow-up. Trough level of tacrolimus at last follow-up was effected by Donor age at transplantation (p=0.028).

Conclusion

Weight control and donor age at transplantation are important to maintain stable transplanted kidney function. Once daily tacrolimus formulation can be safely used in pediatric patients despite of changes in dose and tacrolimus pharmacokinetics.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Choi C, Han A, Min S, Min S-K, Lee T, Jung I-M, Kim S, Ha J. Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-follow-up-after-conversion-from-twice-daily-tacrolimus-formulation-to-once-daily-tacrolimus-formulation-in-pediatric-kidney-transplantation/. Accessed June 1, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences